A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients

被引:40
|
作者
Zhong, Runbo [1 ]
Han, Baohui [1 ]
Zhong, Hua [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Dis, Shanghai 200030, Peoples R China
关键词
Chemoimmunotherapy; Dendritic cell; Cytokine-induced killer cell; Non-small cell lung cancer;
D O I
10.1007/s13277-013-1132-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dendritic cells (DC) play a crucial role in the induction of an effective antitumor immune response. Cytokine-induced killer (CIK) cells, a subset of T lymphocytes, have the capacity to eliminate cancer cells. This study was to evaluate the correlation between the frequency of DC/CIK immunotherapies following regular chemotherapy, the time-to-progression (TTP), and overall survival (OS) of advanced non-small lung cancer patients. Sixty patients with IIIB-IV non-small-cell lung carcinoma (NSCLC) were enrolled from August 2007 to December 2009 and were randomized into two groups. All 60 patients received four courses of navelbine-platinum (NP) chemotherapy. In one group, 30 patients were treated with adoptive autologous DC/CIK cell transfusion twice every 30 days. In the other group, the patients received immunotherapies more than twice every 30 days. The adverse effects, TTP, and OS were evaluated between the two groups. Median survival time of all 60 patients was 13.80 months. The 1-, 2-, and 3-year overall survival rates were 60.0, 21.7, and 15.0 %, respectively. The 1-, 2-, and 3-year overall survival rates of patients receiving more than two immunotherapies were 63.3, 30.0, and 23.3 %, and the rates of those receiving two immunotherapies were 56.7, 13.3, and 6.7 %, respectively. The difference between the two groups was statistically significant (P = 0.037). Compared with patients in the fewer immunotherapies group, TTP in the group receiving more immunotherapies significantly prolonged, with the median improving from 6.2 months (95 % CI, 5.35-9.24) to 7.3 months (95 % CI, 5.45-6.95; P = 0.034). The adverse effects of chemoimmunotherapy were tolerable. Advanced NSCLC patients can benefit from the combination of DC/CIK immunotherapies following conventional chemotherapy. More than two immunotherapies improved TTP and OS of those patients in this study.
引用
收藏
页码:987 / 994
页数:8
相关论文
共 50 条
  • [41] Combination chemotherapy with topotecan for non-small cell lung cancer
    Dowlati, A
    Levitan, N
    LUNG CANCER, 2003, 41 : S23 - S26
  • [42] A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer
    Zhang, Qiang
    Zhu, Xiaoli
    Zhang, Li
    Sun, Siqing
    Huang, Jing
    Lin, Yong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 839 - 846
  • [43] A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer
    Qiang Zhang
    Xiaoli Zhu
    Li Zhang
    Siqing Sun
    Jing Huang
    Yong Lin
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 839 - 846
  • [44] Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?
    Hou, Leng-Chen
    Huang, Fang
    Xu, Hong-Bin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (01) : 23 - 32
  • [45] Efficacy of Chemotherapy for Advanced Non-Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Nishiyama, Osamu
    Kondo, Masashi
    Hasegawa, Yoshinori
    RESPIRATION, 2013, 85 (04) : 326 - 331
  • [46] Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study
    Heraudet, Luc
    Delon, Tara
    Veillon, Remi
    Vergnenegre, Charlotte
    Lepetit, Helene
    Daste, Amaury
    Ravaud, Alain
    Zysman, Maeva
    Domblides, Charlotte
    THORACIC CANCER, 2022, 13 (09) : 1391 - 1400
  • [47] Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer
    Fathi, Amir T.
    Brahmer, Julie R.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 210 - 216
  • [48] Safety and efficacy of cetuximab combined with chemotherapy in Chinese patients with advanced non-small cell lung cancer
    Si, Xiaoyan
    Zhang, Li
    THORACIC CANCER, 2012, 3 (02) : 188 - 193
  • [49] Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
    Korphaisarn, Krittiya
    Danchaivijitr, Pongwut
    Reungwetwattana, Thanyanan
    Chewaskulyong, Busayamas
    Thongthieang, Luangyot
    Chindaprasirt, Jarin
    Maneenil, Kunlatida
    Sathitruangsak, Chirawadee
    Vinayanuwattikun, Chanida
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [50] THE COMBINATION CHEMOTHERAPY OF BEVACIZUMAB PLUS GEMCITABINE AND CARBOPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER
    Kim, Taekyu
    Ahn, Young Mi
    Nam, Seung-hyun
    Kim, Bong-seog
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488